AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 AUG 1 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Naltrexone treatment lowered insulin resistance and reduced body fat mass in obese women with polycystic ovary syndrome, researchers in Italy found.
Franca Fruzzetti and colleagues at the University of Pisa performed an open, controlled clinical trial to determine the effects of naltrexone therapy on obese women with polycystic ovary syndrome (PCOS). The study involved 10 women who received 6 months of naltrexone (50 mg/day) therapy.
Women underwent testing for basal levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), 17beta-estradiol (E[subscript]2), 17-hydroxyprogesterone, total and free T, androstenedione, dehydroepiandrosterone sulfate, cortisol, and sex hormone-binding globulin. Researchers also administered an oral glucose tolerance test and measured the gonadotropin response to gonadotropin-releasing hormone (GnRH) (Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome, Fertility and Sterility, 2002;77(5):936-944).
Over the course of treatment, body mass index (BMI) of the women dropped from 29.94 to 26.07, and the ratio of fasting glucose to insulin improved for women who were insulin-resistant. Hormonal benefits were also apparent. Menstrual cycles became more regular, with an average cycle length ...